Skip to main content
OpenTrials
Completed

NCT Number: NCT06279715

DFI and Aneuploidies

IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure.

Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–43 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinique ovo

Montreal, Quebec, H4P 2S4, Canada

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • IVF cycle completed at clinique ovo
  • Maternal age between 18 to 43 years included
  • PGT-A done on all embryos
  • Recent DFI within 1 year of the IVF cycle

Exclusion criteria

  • Sperm donation

Treatment and study plan

Preimplantation Genetic Testing for Aneuploidy

Other

PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.

Primary outcomes

  1. DFI association and aneuploidy

    Time frame: Up to 3 weeks after embryo fertilization

    Segmental aneuploidy is associated with high levels of sperm DNA fragmentation index

Sponsors and collaborators

Lead sponsor

Clinique Ovo

Industry

Registry information

Official study title

Evaluation of the Association Between the DNA Fragmentation Index (DFI) and the Frequency of Segmental and Total Aneuploidies

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Feb 28, 2024
Registry last updated
Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.